About Prokineticin receptor 1
Prokineticin receptor 1 (PROKR1) is a protein
from Homo sapiens identified by UniProt accession
Q8TCW9, 393 residues long.
MolForge cross-references it against 0 known binders and
103 disease associations.
Target properties
| Protein name | Prokineticin receptor 1 |
|---|
| UniProt accession | Q8TCW9 |
|---|
| Gene | PROKR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 393 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (103)
Diseases linked to this target (Open Targets).
- Hirschsprung disease · score 0.44
- Aganglionic megacolon · score 0.26
- ovarian cancer · score 0.26
- breast adenocarcinoma · score 0.25
- head and neck squamous cell carcinoma · score 0.16
- low grade glioma · score 0.14
- medulloblastoma · score 0.13
- retinitis pigmentosa · score 0.11
- Red cell distribution width · score 0.10
- X-linked retinal dysplasia · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TCW9-F1 | alphafold | PREDICTED | 77.25 | — |
Amino-acid sequence (393 residues)
METTMGFMDD NATNTSTSFL SVLNPHGAHA TSFPFNFSYS DYDMPLDEDE DVTNSRTFFA AKIVIGMALV GIMLVCGIGN FIFIAALVRY KKLRNLTNLL IANLAISDFL VAIVCCPFEM DYYVVRQLSW EHGHVLCTSV NYLRTVSLYV STNALLAIAI DRYLAIVHPL RPRMKCQTAT GLIALVWTVS ILIAIPSAYF TTETVLVIVK SQEKIFCGQI WPVDQQLYYK SYFLFIFGIE FVGPVVTMTL CYARISRELW FKAVPGFQTE QIRKRLRCRR KTVLVLMCIL TAYVLCWAPF YGFTIVRDFF PTVFVKEKHY LTAFYIVECI AMSNSMINTL CFVTVKNDTV KYFKKIMLLH WKASYNGGKS SADLDLKTIG MPATEEVDCI RLK
Explore Prokineticin receptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets